Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 19

recruiting
3 973
countries
28
conditions
2 104

836 trials match your criteria

Nervous system disorder

Recruiting

Study on the Physical Impact of Multiple Sclerosis and Continued Access to Ocrelizumab for Patients Previously in a Related Study

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Ocrelizumab

Juvenile idiopathic arthritis

Recruiting

Study of Sarilumab for Children and Adolescents with Systemic Juvenile Idiopathic Arthritis (sJIA)

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years
  • Substances:Sarilumab

Endometrial cancer+5

Recruiting

Study for Patients with BRCA Mutated Ovarian, Breast, Pancreatic, Prostate, and Endometrial Cancers Continuing Olaparib Treatment

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib

Factor VIII deficiency

Recruiting

Study on Emicizumab and Drug Combination for Patients with Haemophilia A and FVIII Inhibitors

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emicizumab

Seizure

Recruiting

Study on the Safety and Effectiveness of Alprazolam for Treating Long Seizures in Patients Aged 12 and Older

Investigational
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alprazolam

Relapsing-remitting multiple sclerosis

Recruiting

Study on the Effects of IMU-838 (Vidofludimus Calcium) for Patients with Relapsing-Remitting Multiple Sclerosis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Vidofludimus Calcium

Progressive multiple sclerosis

Recruiting

Study on the Effects of Vidofludimus Calcium (IMU-838) in Patients with Progressive Multiple Sclerosis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Vidofludimus Calcium

Systemic lupus erythematosus

Recruiting

Study on Long-Term Safety of Cenerimod for Adults with Moderate-to-Severe Systemic Lupus Erythematosus

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Cenerimod

Breast cancer

Recruiting

Study on the Effectiveness and Safety of Saruparib and Camizestrant in Adults with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib

Anaemia of chronic disease

Recruiting

Study on Efepoetin Alfa and Darbepoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Darbepoetin Alfa

Non-small cell lung cancer

Recruiting

Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib

Acute myeloid leukaemia+3

Recruiting

Title: Long-term treatment study of oral decitabine and cedazuridine combination for patients with AML, MDS, CMML, or solid tumors who previously received ASTX727

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Cedazuridine

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.